Monica R Gadelha, Luiz Eduardo Wildemberg, Leandro Kasuki
doi : 10.1210/clinem/dgab726
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 297–308
Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical control in approximately 40% of patients and tumor shrinkage in over 60% of patients. Pasireotide, a second-generation SRL, shows higher efficacy with respect to both biochemical control and tumor shrinkage but has a worse safety profile. In this review, we discuss the future perspectives of currently available SRLs, focusing on the use of biomarkers of response and precision medicine, new formulations of these SRLs and new drugs, which are under development. Precision medicine, which is based on biomarkers of response to treatment, will help guide the decision-making process by allowing physicians to choose the appropriate drug for each patient and improving response rates. New formulations of available SRLs, such as oral, subcutaneous depot, and nasal octreotide, may improve patients’ adherence to treatment and quality of life since there will be more options available that better suit each patient. Finally, new drugs, such as paltusotine, somatropin, ONO-5788, and ONO-ST-468, may improve treatment adherence and present higher efficacy than currently available drugs.
Roopa Kanakatti Shankar, Tazim Dowlut-McElroy, Andrew Dauber, Veronica Gomez-Lobo Author Notes
doi : 10.1210/clinem/dgab687
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 309–323
Anti-Mullerian hormone (AMH) was originally described in the context of sexual differentiation in the male fetus but has gained prominence now as a marker of ovarian reserve and fertility in females. In this mini-review, we offer an updated synopsis on AMH and its clinical utility in pediatric patients.
Nina Strandkjær, Malene Kongsgaard Hansen, Sofie Taageby Nielsen, Ruth Frikke-Schmidt, Anne Tybjærg-Hansen, Børge G Nordestgaard, Ann Tabor, Henning Bundgaard, Kasper Iversen, Pia R Kamstrup
doi : 10.1210/clinem/dgab734
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 324–335
High lipoprotein(a) is a genetically determined causal risk factor for cardiovascular disease, and 20% of the adult population has high levels (ie, >42 mg/dL, >88 nmol/L). We investigated whether early life lipoprotein(a) levels measured in cord blood may serve as a proxy for neonatal venous blood levels, whether lipoprotein(a) birth levels (ie, cord or venous) predict levels later in life, and whether early life and parental levels correlate.
Gal Tsaban, Anat Yaskolka Meir, Hila Zelicha, Ehud Rinott, Alon Kaplan, Aryeh Shalev, Amos Katz, Dov Brikner, Matthias Blüher, Uta Ceglarek, Michael Stumvoll, Meir J Stampfer, Iris Shai
doi : 10.1210/clinem/dgab681
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 336–345
Lower fasting ghrelin levels (FGL) are associated with obesity and metabolic syndrome.
Vinaya Simha, Ian R Lanza, Surendra Dasari, Katherine A Klaus, Nathan Le Brasseur, Ivan Vuckovic, Marcello C Laurenti, Claudio Cobelli, John D Port, K Sreekumaran Nair
doi : 10.1210/clinem/dgab725
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 346–362
Familial partial lipodystrophy (FPL), Dunnigan variety is characterized by skeletal muscle hypertrophy and insulin resistance besides fat loss from the extremities. The cause for the muscle hypertrophy and its functional consequences is not known.
Valentina Pirro, Kenneth D Roth, Yanzhu Lin, Jill A Willency, Paul L Milligan, Jonathan M Wilson, Giacomo Ruotolo, Axel Haupt, Christopher B Newgard, Kevin L Duffin
doi : 10.1210/clinem/dgab722
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 363–378
Tirzepatide substantially reduced hemoglobin A1c (HbA1c) and body weight in subjects with type 2 diabetes (T2D) compared with the glucagon-like peptide 1 receptor agonist dulaglutide. Improved glycemic control was associated with lower circulating triglycerides and lipoprotein markers and improved markers of beta-cell function and insulin resistance (IR), effects only partially attributable to weight loss.
Cuiqi Zhou, Stephen Shen, Rosemary Moran, Nan Deng, Eduardo Marbán, Shlomo Melmed
doi : 10.1210/clinem/dgab651
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 379–397
The identification and biological actions of pituitary-derived exosomes remain elusive.
Tibor V Varga, Tianwei Xu, Mika Kivimäki, Amar J Mehta, Reiner Rugulies, Naja H Rod
doi : 10.1210/clinem/dgab704
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 398–409
Organizational justice has been linked to lower risk of several chronic conditions among employees, but less is known about the long-term mechanisms underlying this risk reduction.
Carla Demeterco-Berggren, Osagie Ebekozien, Saketh Rompicherla, Laura Jacobsen, Siham Accacha, Mary Pat Gallagher, G Todd Alonso, Berhane Seyoum, Francesco Vendrame, J Sonya Haw, Marina Basina, Carol J Levy, David M Maahs
doi : 10.1210/clinem/dgab668
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 410–418
COVID-19 morbidity and mortality are increased in type 1 diabetes (T1D), but few data focus on age-based outcomes.
Kelly De Sousa, Alaa B Abdellatif, Isabelle Giscos-Douriez, Tchao Meatchi, Laurence Amar, Fabio L Fernandes-Rosa, Sheerazed Boulkroun, Maria-Christina Zennaro
doi : 10.1210/clinem/dgab707
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 419–434
Aldosterone-producing adenomas (APAs) are a common cause of primary aldosteronism (PA). Despite the discovery of somatic mutations in APA and the characterization of multiple factors regulating adrenal differentiation and function, the sequence of events leading to APA formation remains to be determined.
Carl Jenkinson, Reena Desai, Malcolm D McLeod, Jonathan Wolf Mueller, Martin Hewison, David J Handelsman
doi : 10.1210/clinem/dgab708
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 435–449
Vitamin D status is conventionally defined by measurement of unconjugated circulating 25-hydroxyvitamin D (25OHD), but it remains uncertain whether this isolated analysis gives sufficient weight to vitamin D’s diverse metabolic pathways and bioactivity. Emerging evidence has shown that phase II endocrine metabolites are important excretory or storage forms; however, the clinical significance of circulating phase II vitamin D metabolites remains uncertain.
Claudia I Maushart, Jaël R Senn, Rahel C Loeliger, Judith Siegenthaler, Fabienne Bur, Jonas G W Fischer, Matthias J Betz
doi : 10.1210/clinem/dgab706
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 450–461
Thyroid hormone (TH) is crucial for the adaptation to cold.
Lu Lyu, Jie Yu, Yiwen Liu, Shuli He, Yuan Zhao, Mengya Qi, Fan Ping, Lingling Xu, Wei Li, Huabing Zhang, Yuxiu Li
doi : 10.1210/clinem/dgab703
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 462–473
The hemoglobin glycation index (HGI) is correlated with metabolic diseases and inflammation. Whether the HGI is associated with the aging process and how inflammation and oxidative stress affect the relationship remain unclear.
Shaojian Lin, Yue Zhu, Chengcheng Ji, Weiming Yu, Cheng Zhang, Langping Tan, Miaoyun Long, Dingyuan Luo, Xinzhi Peng
doi : 10.1210/clinem/dgab480
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 474–490
Abnormally high expression of N6-methyladenosine (m6A) methyltransferase-like 3 (METTL3) has been implied to accompany thyroid carcinoma (TC) development.
Gregory A Kline, Suzanne N Morin, Lisa M Lix, William D Leslie
doi : 10.1210/clinem/dgab696
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 491–499
Fracture on therapy should motivate better antifracture medication adherence.
Alexander Lutsenko, Zhanna Belaya, Alexey Nikitin, Alexander Solodovnikov, Anastasia Lapshina, Philipp Koshkin, Maria Vorontsova, Liudmila Rozhinskaya, Galina Melnichenko, Ivan Dedov
doi : 10.1210/clinem/dgab695
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 500–511
Excessive production of growth hormone causes marked multiorgan changes in patients with acromegaly, which may involve epigenetic mechanisms.
Joost Brinks, Elon H C van Dijk, Szymon M Kiełbasa, Hailiang Mei, Isa van der Veen, Hendrika A B Peters, Hetty C M Sips, Robbert G E Notenboom, Paul H A Quax, Camiel J F Boon, Onno C Meijer
doi : 10.1210/clinem/dgab670
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 512–524
Central serous chorioretinopathy (CSC) is a severe ocular disease characterized by fluid accumulation under the retina and abnormalities in the underlying vascular layer, the choroid. CSC has a striking prevalence in males of 80% to 90% of total patients. Corticosteroids are the most pronounced extrinsic risk factor for CSC. Choroidal endothelial cells (CECs) are important for the vascular integrity of the choroid, but the effects of corticosteroid effects in these cells are unknown.
Cora M Best, Leila R Zelnick, Kenneth E Thummel, Simon Hsu, Christine Limonte, Ravi Thadhani, Howard D Sesso, JoAnn E Manson, Julie E Buring, Samia Mora, I-Min Lee, Nancy R Cook, Georgina Friedenberg, Heike Luttmann-Gibson, Ian H de Boer, Andrew N Hoofnagle
doi : 10.1210/clinem/dgab693
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 525–537
The effect of daily vitamin D supplementation on the serum concentration of vitamin D (the parent compound) may offer insight into vitamin D disposition.
Martine Paquette, Sophie Bernard, Guillaume Paré, Alexis Baass
doi : 10.1210/clinem/dgab648
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 538–548
Dysbetalipoproteinemia (DBL) is characterized by the accumulation of remnant lipoprotein particles and associated with an increased risk of cardiovascular and peripheral vascular disease (PVD). DBL is thought to be mainly caused by the presence of an E2/E2 genotype of the apolipoprotein E (APOE) gene, in addition to environmental factors. However, there exists considerable phenotypic variability among DBL patients.
Anira Iqbal, Keren Zhou, Sangeeta R Kashyap, M Cecilia Lansang
doi : 10.1210/clinem/dgab697
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 549–562
Though posttransplant diabetes mellitus (PTDM, occurring > 45 days after transplantation) and its complications are well described, early post–renal transplant hyperglycemia (EPTH) (< 45 days) similarly puts kidney transplant recipients at risk of infections, rehospitalizations, and graft failure and is not emphasized much in the literature. Proactive screening and management of EPTH is required given these consequences.
Dong Yeong Kim, Pyeong Hwa Kim, Ah Young Jung, Jin-Ho Choi, Young Ah Cho, Hee Mang Yoon, Jin Seong Lee
doi : 10.1210/clinem/dgab732
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 563–574
Pituitary stalk thickening (PST) is often identified on magnetic resonance imaging (MRI), either incidentally or during diagnostic workup of hypopituitarism. However, the neoplastic etiology and natural course of PST are not fully understood, although this knowledge is required to establish diagnostic and surveillance strategies.
Carrie Riestenberg, Anika Jagasia, Daniela Markovic, Richard P Buyalos, Ricardo Azziz
doi : 10.1210/clinem/dgab613
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 575–585
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of reproductive-aged women, affecting approximately 5% to 20% of women of reproductive age. The economic burden of PCOS was previously estimated at approximately $3.7 billion annually in 2020 USD when considering only the costs of the initial diagnosis and of reproductive endocrine morbidities, without considering the costs of pregnancy-related and long-term morbidities.
Chun-Ta Huang, Chi-Yu Lee, Heng-You Sung, Shu-Jung Liu, Po-Chih Liang, Ming-Chieh Tsai
doi : 10.1210/clinem/dgab675
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages 586–597
Individuals with diabetes mellitus (DM) are susceptible to various infections.
Brian W Kim
doi : 10.1210/clinem/dgab700
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e448–e457
Radioactive iodine has been considered a safe and effective therapeutic option for hyperthyroidism secondary to Graves disease and autonomously functioning thyroid nodules since the mid-20th century. The question of whether I-131 at the doses used for hyperthyroidism might increase the risk of cancer has been investigated in a number of observational cohort studies over the years, with the preponderance of evidence being reassuring as to its safety. In particular, the 1998 Cooperative Thyrotoxicosis Therapy Follow-up Study (CTTFUS) has been widely cited as compelling evidence that I-131 is safe in hyperthyroidism therapy with respect to carcinogenesis. However, in 2019, a study by Kitahara and colleagues re-analyzed the CTTFUS cohort, extending the follow-up time and applying a novel dosimetric model for estimating tissue absorbed doses of radiation. This new analysis concluded that radioactive iodine was associated with an increased risk for mortality from overall cancer, breast cancer, and non-breast solid cancers. Reaction to this study was vociferous and particularly negative in the nuclear medicine literature. This mini-review was inspired by the 2019 CTTFUS controversy, and it is intended to provide the necessary context for clinicians to provide nuanced advice to their patients on the subject. To that end, the pre-2019 literature is surveyed, the 2019 CTTFUS study and a 2020 follow-up are discussed, and lessons from the literature and critical commentaries are considered.
Marieke Tebbens, Annemieke C Heijboer, Guy T’Sjoen, Peter H Bisschop, Martin den Heijer
doi : 10.1210/clinem/dgab741
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e458–e466
In trans women, hormone treatment induces feminization; however, the degree of feminization varies from person to person. A possible contributing factor could be estrone, a weak estrogen that interferes with the estrogen receptor.
Susanna C Larsson, Siddhartha Kar, John R B Perry, Paul Carter, Mathew Vithayathil, Amy M Mason, Douglas F Easton, Stephen Burgess
doi : 10.1210/clinem/dgab713
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e467–e474
The causal role of endogenous estradiol in cancers other than breast and endometrial cancer remains unclear.
Henrik Falhammar, Louise Frisén, Angelica Lindén Hirschberg, Agneta Nordenskjöld, Catarina Almqvist, Anna Nordenström
doi : 10.1210/clinem/dgab712
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e475–e486
Low bone mineral density has been reported in individuals with congenital adrenal hyperplasia (CAH), but the prevalence of fractures is unclear.
Tobias Troger, Grit Sommer, Mariarosaria Lang-Muritano, Daniel Konrad, Beatrice Kuhlmann, Urs Zumsteg, Christa E Flück
doi : 10.1210/clinem/dgab701
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e487–e499
Patients with classic congenital adrenal hyperplasia (CAH) often do not achieve their full growth potential. Adrenarche may accelerate bone maturation and thereby result in decreased growth in CAH.
Matthew C Babcock, Lyndsey E DuBose, Teresa L Witten, Brian L Stauffer, Kerry L Hildreth, Robert S Schwartz, Wendy M Kohrt, Kerrie L Moreau
doi : 10.1210/clinem/dgab715
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e500–e514
Vascular aging, including endothelial dysfunction secondary to oxidative stress and inflammation, increases the risk for age-associated cardiovascular disease (CVD). Low testosterone in middle-aged/older men is associated with increased CVD risk.
Sangmo Hong, Jung Hwan Park, Kyungdo Han, Chang Beom Lee, Dong Sun Kim, Sung Hoon Yu
doi : 10.1210/clinem/dgab714
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e515–e527
Some studies have suggested that patients with type 2 diabetes mellitus (T2DM) concomitant with obesity have better clinical outcomes than normal-weight patients with T2DM.
Saila Laakso, Elina Holopainen, Corrado Betterle, Viivi Saari, Elinor Vogt, Monica M Schmitt, Karen K Winer, Maria Kareva, Chiara Sabbadin, Eystein S Husebye, Elizaveta Orlova, Michail S Lionakis, Outi Mäkitie
doi : 10.1210/clinem/dgab705
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e528–e537
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED; also known as autoimmune polyendocrine syndrome type 1) has a severe, unpredictable course. Autoimmunity and disease components may affect fertility and predispose to maternal and fetal complications, but pregnancy outcomes remain unknown.
Olivia M DeLozier, Sophie Y Dream, James W Findling, Ty B Carroll, Douglas B Evans, Tracy S Wang
doi : 10.1210/clinem/dgab698
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e538–e547
An institutional study previously demonstrated that cosyntropin stimulation testing on postoperative day 1 (POD1-CST) identified patients at risk for adrenal insufficiency (AI) following unilateral adrenalectomy (UA) for adrenal-dependent hypercortisolism (HC) and primary aldosteronism (PA), allowing for selective glucocorticoid replacement (GR).
Christine L Chan, Laura Pyle, Tim Vigers, Philip S Zeitler, Kristen J Nadeau
doi : 10.1210/clinem/dgab692
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e548–e560
Early glucose abnormalities in people with cystic fibrosis (PwCF) are commonly detected by continuous glucose monitoring (CGM). Relationships between these CGM abnormalities and oral glucose tolerance testing (OGTT) in PwCF have not been fully characterized.
Albert Shieh, Kristine M Ruppert, Gail A Greendale, Yinjuan Lian, Jane A Cauley, Sherri-Ann Burnett-Bowie, Carrie Karvonen-Guttierez, Arun S Karlamangla
doi : 10.1210/clinem/dgab690
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e561–e569
Menopause before age 45 is a risk factor for fractures, but menopause occurs at age ≥45 in ~90% of women.
Anass El Malahi, Michiel Van Elsen, Sara Charleer, Eveline Dirinck, Kristien Ledeganck, Bart Keymeulen, Laurent Crenier, Régis Radermecker, Youri Taes, Chris Vercammen, Frank Nobels, Chantal Mathieu, Pieter Gillard, Christophe De Block
doi : 10.1210/clinem/dgab688
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e570–e581
Real-time continuous glucose monitoring (RT-CGM) provides information on glycemic variability (GV), time in range (TIR), and guidance to avoid hypoglycemia, thereby complimenting HbA1c for diabetes management. We investigated whether GV and TIR were independently associated with chronic and acute diabetes complications.
Rosemarie Krug, Laura Beier, Michael Lämmerhofer, Manfred Hallschmid
doi : 10.1210/clinem/dgab689
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e582–e593
Systematic investigations into the cognitive impact of estradiol and insulin in male individuals are sparse, and it is unclear whether the 2 hormones interact to benefit specific cognitive functions in humans.
Juilee Rege, Jessie Hoxie, Chia-Jen Liu, Morgan N Cash, James M Luther, Lan Gellert, Adina F Turcu, Tobias Else, Thomas J Giordano, Aaron M Udager, William E Rainey, Kazutaka Nanba
doi : 10.1210/clinem/dgab682
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e594–e603
Somatic gene mutations have been identified in only about half of cortisol-producing adenomas (CPAs). Affected genes include PRKACA, GNAS, PRKAR1A, and CTNNB1.
Bernadette L Dekker, Mirthe H Links, Anneke C Muller Kobold, Linda G Swart-Busscher, Marleen Kars, Judith A P Bons, Adrienne H Brouwers, Thera P Links, Anouk N A van der Horst-Schrivers
doi : 10.1210/clinem/dgab691
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e604–e611
No consensus exists about the optimal duration of the low-iodine diet (LID) in the preparation of 131I therapy in differentiated thyroid cancer (DTC) patients.
Elena Castellano, Roberto Attanasio, Alberto Boriano, Micaela Pellegrino, Giorgio Borretta
doi : 10.1210/clinem/dgab676
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e612–e618
Although the inverse correlation between serum PTH and phosphate (P) levels in patients with primary hyperparathyroidism (PHPT) is well known, the relationship between P levels and the clinical picture of the disease has not been well investigated. This was thus the aim of this paper.
Tammy Lo, Renuka S Haridas, Eleanor J M Rudge, Robert P Chase, Keyvan Heshmati, Elizabeth M Lucey, Alison M Weigl, Otatade J Iyoha-Bello, Chelsea O Ituah, Emily J Benjamin, Seth W McNutt, Leena Sathe, Leanna Farnam, Benjamin A Raby, Ali Tavakkoli, Damien C Croteau-Chonka, Eric G Sheu
doi : 10.1210/clinem/dgab673
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e619–e630
To characterize longitudinal changes in blood biomarkers, leukocyte composition, and gene expression following laparoscopic sleeve gastrectomy (LSG).
Clara Amalie Gade Timmermann, Marianne Skovsager Andersen, Esben Budtz-Jørgensen, Henriette Boye, Flemming Nielsen, Richard Christian Jensen, Signe Bruun, Steffen Husby, Philippe Grandjean, Tina Kold Jensen
doi : 10.1210/clinem/dgab638
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e631–e642
Human exposure to perfluoroalkyl substances (PFAS) has been associated with reduced duration of breastfeeding, although not consistently so, and mechanisms by which PFAS might affect breastfeeding are unknown.
Nicolien A van Vliet, Annelies E P Kamphuis, Wendy P J den Elzen, Gerard J Blauw, Jacobijn Gussekloo, Raymond Noordam, Diana van Heemst
doi : 10.1210/clinem/dgab674
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e643–e652
Thyroid dysfunction is associated with higher anemia prevalence, although causality remains unclear.
Erika B Parente, Valma Harjutsalo, Carol Forsblom, Per-Henrik Groop
doi : 10.1210/clinem/dgab671
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e653–e662
Obesity prevalence has increased in type 1 diabetes (T1D). However, the relationship between body composition and severe diabetic eye disease (SDED) is unknown.
Alon Peled, Itamar Raz, Inbar Zucker, Estela Derazne, Jacob Megreli, Orit Pinhas-Hamiel, Adi Einan-Lifshitz, Yair Morad, Eran Pras, Miri Lutski, Tali Cukierman-Yaffe, Ofri Mosenzon, Dorit Tzur, Amir Tirosh, Hertzel C Gerstein, Arnon Afek, Gilad Twig
doi : 10.1210/clinem/dgab669
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e663–e671
A correlation between myopia and insulin resistance has been suggested.
Laura Potasso, Julie Refardt, Gian Marco De Marchis, Andrea Wiencierz, Patrick R Wright, Benjamin Wagner, Tolga Dittrich, Alexandros A Polymeris, Henrik Gensicke, Leo H Bonati, Mirjam Christ-Crain
doi : 10.1210/clinem/dgab650
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e672–e680
Correction of hyponatremia might represent an additional treatment for improving stroke patients’ clinical outcomes.
Zentaro Kiuchi, Monica Reyes, Patrick Hanna, Anu Sharma, Terry DeClue, Robert C Olney, Peter Tebben, Harald Jüppner
doi : 10.1210/clinem/dgab660
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e681–e687
Maternally inherited STX16 deletions that cause loss of methylation at GNAS exon A/B and thereby reduce Gsα expression are the most frequent cause of autosomal dominant pseudohypoparathyroidism type Ib (AD-PHP1B). Early identification of these disease-causing variants in the children of affected and unaffected female carriers would prompt treatment with calcium and calcitriol once parathyroid hormone (PTH) levels increase, thereby preventing hypocalcemia and associated complications.
Rong Huang, Yu Dong, Emile Levy, Pierre Julien, Isabelle Marc, Hua He, Ya-Jie Xu, Shu-Qin Wei, William D Fraser, Zhong-Cheng Luo
doi : 10.1210/clinem/dgab642
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e688–e697
Fetal overgrowth “programs� an elevated risk of obesity and type 2 diabetes in adulthood. Plausibly, adipokines may be involved in programming metabolic health.
Andrea S Foulkes, Caitlin Selvaggi, Daniel Shinnick, Heidi Lumish, Eunyoung Kim, Tingyi Cao, Tanayott Thaweethai, Jing Qian, Frances Lu, Joyce Yan, David Cheng, Wei He, Kevin J Clerkin, Mahesh V Madhavan, James B Meigs, Virginia A Triant, Steven A Lubitz, Aakriti Gupta, Ingrid V Bassett, Muredach P Reilly
doi : 10.1210/clinem/dgab629
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e698–e707
Obesity is an established risk factor for severe COVID-19 outcomes. The mechanistic underpinnings of this association are not well-understood.
Leonie C Ruddick-Collins, Alan Flanagan, Jonathan D Johnston, Peter J Morgan, Alexandra M Johnstone
doi : 10.1210/clinem/dgab654
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e708–e715
Daily variation in the thermic effect of food (TEF) is commonly reported and proposed as a contributing factor to weight gain with late eating. However, underlying circadian variability in resting metabolic rate (RMR) is an overlooked factor when calculating TEF associated with eating at different times of the day.
Chao Chin Hsu, Isabel Hsu, Hui Hua Chang, Rosie Hsu, Sonam Dorjee
doi : 10.1210/clinem/dgab709
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e716–e733
Gonadotropins can be administered every 5 days under intradermal injection in in vitro fertilization (IVF) treatment.
Karen L Lindsay, Lauren E Gyllenhammer, Sonja Entringer, Pathik D Wadhwa
doi : 10.1210/clinem/dgab655
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e734–e744
Hispanic women are at elevated risk of gestational glucose intolerance and postpartum type 2 diabetes compared with non-Hispanic White women. Identification of potentially modifiable factors contributing to this trajectory of beta-cell dysfunction is warranted.
Xiaomo Wang, Shouling Wu, Xiaojie Yuan, Shuohua Chen, Qingjiang Fu, Yuanyuan Sun, Yanqi Lan, Shiqi Hu, Yanhong Wang, Ying Lu,Shunxi Qu, Li Wang
doi : 10.1210/clinem/dgab644
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e745–e755
Nonalcoholic fatty liver disease (NAFLD) was renamed metabolic dysfunction associated with fatty liver disease (MAFLD) recently.
Farhat Fatima, Jøran Hjelmesæth, Kåre Inge Birkeland, Hanne Løvdal Gulseth, Jens Kristoffer Hertel, Marius Svanevik, Rune Sandbu, Milada Cvancarova Småstuen, Bolette Hartmann, Jens Juul Holst, Dag Hofsø
doi : 10.1210/clinem/dgab643
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e756–e766
Whether Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) differentially affect postprandial gastrointestinal hormones and β-cell function in type 2 diabetes remains unclear.
Ben Jones, Caroline Sands, Kleopatra Alexiadou, James Minnion, George Tharakan, Preeshila Behary, Ahmed R Ahmed, Sanjay Purkayastha, Matthew R Lewis, Stephen Bloom,Jia V Li, Tricia M Tan
doi : 10.1210/clinem/dgab608
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e767–e782
The gut-derived peptide hormones glucagon-like peptide-1 (GLP-1), oxyntomodulin (OXM), and peptide YY (PYY) are regulators of energy intake and glucose homeostasis and are thought to contribute to the glucose-lowering effects of bariatric surgery.
Priyanka Singh, Sanjay Kumar Bhadada, Ashutosh Kumar Arya, Uma Nahar Saikia, Naresh Sachdeva, Divya Dahiya, Jyotdeep Kaur, Maria Luisa Brandi, Sudhaker Dhanwada Rao
doi : 10.1210/clinem/dgab626
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e783–e792
Primary hyperparathyroidism (PHPT) results from the hypersecretion of parathyroid hormone from parathyroid tumors. A transcription factor, namely Paired box1 (PAX1), is active in parathyroid gland development.
Komal Waqas, Jinluan Chen, Katerina Trajanoska, M Arfan Ikram, André G Uitterlinden, Fernando Rivadeneira, M Carola Zillikens
doi : 10.1210/clinem/dgab632
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e793–e803
Accumulation of advanced glycation end-products (AGEs) in skeletal muscle has been implicated in development of sarcopenia.
Yi Wang, Fengjiang Sun, Ping Wu, Yichao Huang, Yi Ye, Xue Yang, Jiaying Yuan, Yan Liu, Huayan Zeng, Ying Wen, Xiaorong Qi, Chun-Xia Yang, Yixin Wang, Gang Liu, Da Chen, Liangzhong Li, Xiong-Fei Pan, An Pan
doi : 10.1210/clinem/dgab637
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e804–e814
While the associations between thyroid markers and gestational diabetes mellitus (GDM) have been extensively studied, the results are inconclusive and the mechanisms remain unclear.
Panpan He, Huan Li, Mengyi Liu, Zhuxian Zhang, Yuanyuan Zhang, Chun Zhou, Qinqin Li, Chengzhang Liu, Xianhui Qin
doi : 10.1210/clinem/dgab636
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e815–e824
We aimed to investigate the relationship of dietary zinc intake with new-onset diabetes among Chinese adults.
Chaojie Ye, Lijie Kong, Zhiyun Zhao, Mian Li, Shuangyuan Wang, Hong Lin, Yu Xu, Jieli Lu, Yuhong Chen, Yiping Xu, Weiqing Wang, Guang Ning, Yufang Bi, Min Xu, Tiange Wang
doi : 10.1210/clinem/dgab633
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e825–e835
Observational studies have been associated obesity with chronic kidney disease (CKD) and arterial stiffness, but the causality remains unclear.
Martha Hanschkow, Nathalie Boulet, Elena Kempf, Anne Bouloumié, Wieland Kiess, Robert Stein, Antje Körner, Kathrin Landgraf
doi : 10.1210/clinem/dgab630
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e836–e851
MSCA1 (mesenchymal stem cell antigen 1) and CD36 (cluster of differentiation 36) have been described as novel adipocyte progenitor markers in adults with a potential relevance for obesity and adipocyte progenitor function.
Christin Volk, Benjamin Schmidt, Corinna Brandsch, Tabea Kurze, Ulf Schlegelmilch, Ivo Grosse, Christof Ulrich, Matthias Girndt, Gabriele I Stangl
doi : 10.1210/clinem/dgab635
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e852–e864
Hyperphosphatemia and high levels of fibroblast growth factor 23 (FGF23) are risk factors for cardiovascular events in patients with chronic kidney diseases. However, the impact of an inorganic phosphorus additive in healthy people is largely unknown.
Carmina Teresa Fuss, Katharina Brohm, Martin Fassnacht, Matthias Kroiss, Stefanie Hahner
doi : 10.1210/clinem/dgab611
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e865–e873
Adrenal vein sampling (AVS) represents the current diagnostic gold standard for differentiation between unilateral and bilateral primary aldosteronism (PA). Postural stimulation testing (PST) has been used to provide additional diagnostic information.
Ellen A Schur, Jenny Tong
doi : 10.1210/clinem/dgab661
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e874–e876
Gijs H Goossens
doi : 10.1210/clinem/dgab699
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e877–e879
Eva Kassi, Gregory Kaltsas
doi : 10.1210/clinem/dgab683
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e880–e882
Rafael Ferraz-Bannitz, Sangeeta Kashyap, Mary Elizabeth Patti
doi : 10.1210/clinem/dgab694
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e883–e885
Erik K Alexander
doi : 10.1210/clinem/dgab423
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e886–e887
Lars Sävendahl, Tadej Battelino, Meryl Brod, Michael Højby Rasmussen, Rasmus Juul Kildemoes, Paul Saenger
doi : 10.1210/clinem/dgab736
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e888–e889
Pierre Bougnères
doi : 10.1210/clinem/dgab716
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e890–e891
Gian Paolo Rossi, Giacomo Rossitto
doi : 10.1210/clinem/dgab717
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e892–e893
Helen B Chin, Andrea Kelly, Margaret A Adgent, Stacy A Patchel, Kerry James, Donald Walt Chandler, Babette S Zemel, Joan I Schall, Eileen G Ford, Kassa Darge, Virginia A Stallings, Donna D Baird, Walter J Rogan, David M Umbach
doi : 10.1210/clinem/dgab718
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e894–e895
Silvia Monticone, Franco Veglio, Paolo Mulatero
doi : 10.1210/clinem/dgab719
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Pages e896–e897
doi : 10.1210/clinem/dgab625
The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 2, February 2022, Page e898
Do you want to add Medilib to your home screen?